Noor Rashed
Department of Life Sciences (DLS), School of Environment and Life Sciences (SELS), Independent University, Bangladesh (IUB), Plot 16, Block B, Aftabuddin Ahmed Road, Bashundhara, Dhaka 1229 Bangladesh.
Curr Clin Microbiol Rep. 2021;8(3):178-185. doi: 10.1007/s40588-021-00162-y. Epub 2021 Mar 3.
Along with the continued in silico-based studies for drug designing and repurposing followed by the corresponding cell culture studies, the ongoing clinical trials with some completed regarding finding the drug efficacy and the vaccine development against the severe acute respiratory coronavirus 2 (SARS-CoV-2) have been the most functional and indispensable issue during the current COVID-19 pandemic within 2020 and onward. The present review attempted to figure out the update on this effective vaccine and discussed the other promising vaccines.
A range of investigations on the SARS-CoV-2 genomics, on its similarities with SARS-CoV-1, and with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been accomplished and the host immune dodging mechanisms by the SARS-CoV-2 have been unraveled which in turn led the scientists around the world to work rigorously on the vaccine development. Working with various vaccine platforms so far revealed the efficacy of the mRNA-1273 vaccine as the most effective one as resulted through the clinical trials which resulted in 95% positive output.
Although currently commercialized mRNA-1273 vaccine appears to be effective, still several points are to be pondered regarding the sustainability of vaccine efficacy against the rising variants of SARS-CoV-2.
在基于计算机模拟进行药物设计和重新利用研究，并开展相应细胞培养研究的同时，针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）开展的药物疗效及疫苗研发的临床试验（其中一些已经完成），一直是2020年及之后新冠疫情期间最具作用且不可或缺的事项。本综述试图梳理这种有效疫苗的最新情况，并讨论其他有前景的疫苗。
已经完成了一系列关于SARS-CoV-2基因组学、其与SARS-CoV-1以及中东呼吸综合征冠状病毒（MERS-CoV）相似性的研究，并且揭示了SARS-CoV-2的宿主免疫逃避机制，这反过来促使世界各地的科学家在疫苗研发方面进行严格攻关。目前使用各种疫苗平台开展的工作表明，mRNA-1273疫苗经临床试验证明是最有效的，阳性产出率达95%。
尽管目前已商业化的mRNA-1273疫苗似乎有效，但针对SARS-CoV-2不断出现的变种，疫苗疗效的可持续性仍有几点需要思考。
